# Fabian Weykamp

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8009895/publications.pdf

Version: 2024-02-01

| 19 | 292 | 933447 | 940533 |
|---|---|---|---|
| papers | citations | 10 h-index | 16 g-index |

| 20 | 20 | 20 | 371 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial). International Journal of Radiation Oncology Biology Physics, 2021, 109, 1311-1324. | 0.8 | 37 |
| 2 | Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. Radiation Oncology, 2020, 15, 30. | 2.7 | 36 |
| 3 | Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer. Cancers, 2021, 13, 796. | 3.7 | 32 |
| 4 | Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Liver Tumors: Initial Clinical Experience and Patient-Reported Outcomes. Frontiers in Oncology, 2021, 11, 610637. | 2.8 | 31 |
| 5 | Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung. Frontiers in Oncology, 2020, 10, 564857. | 2.8 | 19 |
| 6 | Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer. Frontiers in Oncology, 2020, 10, 987. | 2.8 | 19 |
| 7 | Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations. Frontiers in Oncology, 2021, 11, 757031. | 2.8 | 17 |
| 8 | Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. Frontiers in Oncology, 2020, 10, 989. | 2.8 | 15 |
| 9 | Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin. Strahlentherapie Und Onkologie, 2020, 196, 515-521. | 2.0 | 13 |
| 10 | Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme. Clinical Lung Cancer, 2020, 22, 332-340.e3. | 2.6 | 11 |
| 11 | Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3). Radiation Oncology, 2022, 17, . | 2.7 | 11 |
| 12 | Active-Scanned Protons and Carbon Ions in Cancer Treatment of Patients With Cardiac Implantable Electronic Devices: Experience of a Single Institution. Frontiers in Oncology, 2019, 9, 798. | 2.8 | 10 |
| 13 | Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective. Frontiers in Oncology, 2020, 10, 592796. | 2.8 | 10 |
| 14 | SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes. Radiotherapy and Oncology, 2022, 168, 106-112. | 0.6 | 10 |
| 15 | Stereotactic body radiotherapy of lymph node metastases under MR-guidance: First clinical results and patient-reported outcomes. Strahlentherapie Und Onkologie, 2022, 198, 56-65. | 2.0 | 8 |
| 16 | Effectiveness of Carbon Ion Radiation in Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 708884. | 2.8 | 5 |
| 17 | Validation of Nine Different Prognostic Grading Indexes for Radiosurgery of Brain Metastases in Breast Cancer Patients and Development of an All-Encompassing Prognostic Tool. Frontiers in Oncology, 2020, 10, 1557. | 2.8 | 4 |
| 18 | Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors. Cancers, 2020, 12, 2862. | 3.7 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Adjuvant Radiation Therapy for Male Breast Cancerâ€"A Rare Indication?. Cancers, 2020, 12, 3645. | 3.7 | 1 |